According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Subscribe To Our Newsletter & Stay Updated
